Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corwin A Robertson

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
South Dakota Medicine : the Journal of the South Dakota State Medical Association|March 1, 2013
The science of vaccination: establishing safety and efficacyCorwin A Robertson
Pediatric Annals|August 6, 2013
Prevention and control of influenza and dengue through vaccine developmentDavid P Greenberg, Corwin A Robertson, Daniel M Gordon
Vaccine|January 24, 2019
Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D)Corwin A Robertson, James Hedrick, Ehab Bassily, et al.
Human Vaccines & Immunotherapeutics|January 12, 2023
Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized studyCorwin A Robertson, Jeffry Jacqmein, Alexandre Selmani, et al.
Human Vaccines & Immunotherapeutics|November 18, 2024
Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of ageCorwin A Robertson, Jeffry Jacqmein, Alexandre Selmani, et al.
Human Vaccines & Immunotherapeutics|August 10, 2022
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of ageGary S Marshall, Stephen I Pelton, Corwin A Robertson, et al.
Expert Review of Vaccines|July 27, 2016
Fluzone® Intradermal Quadrivalent Influenza VaccineCorwin A Robertson, Peter Tsang, Victoria A Landolfi, et al.
Human Vaccines & Immunotherapeutics|July 13, 2017
Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and olderDavid P Greenberg, Corwin A Robertson, H Keipp Talbot, et al.
Emerging Infectious Diseases|June 8, 2007
Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004Esther T Tan, Corwin A Robertson, Shereen Brynildsen, et al.
Vaccine|September 20, 2016
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccineCorwin A Robertson, David P Greenberg, James Hedrick, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
South Dakota Medicine : the Journal of the South Dakota State Medical Association|March 1, 2013
The science of vaccination: establishing safety and efficacyCorwin A Robertson
Pediatric Annals|August 6, 2013
Prevention and control of influenza and dengue through vaccine developmentDavid P Greenberg, Corwin A Robertson, Daniel M Gordon
Vaccine|January 24, 2019
Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D)Corwin A Robertson, James Hedrick, Ehab Bassily, et al.
Human Vaccines & Immunotherapeutics|January 12, 2023
Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized studyCorwin A Robertson, Jeffry Jacqmein, Alexandre Selmani, et al.
Human Vaccines & Immunotherapeutics|November 18, 2024
Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of ageCorwin A Robertson, Jeffry Jacqmein, Alexandre Selmani, et al.
Human Vaccines & Immunotherapeutics|August 10, 2022
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of ageGary S Marshall, Stephen I Pelton, Corwin A Robertson, et al.
Expert Review of Vaccines|July 27, 2016
Fluzone® Intradermal Quadrivalent Influenza VaccineCorwin A Robertson, Peter Tsang, Victoria A Landolfi, et al.
Human Vaccines & Immunotherapeutics|July 13, 2017
Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and olderDavid P Greenberg, Corwin A Robertson, H Keipp Talbot, et al.
Emerging Infectious Diseases|June 8, 2007
Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004Esther T Tan, Corwin A Robertson, Shereen Brynildsen, et al.
Vaccine|September 20, 2016
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccineCorwin A Robertson, David P Greenberg, James Hedrick, et al.
Pageof 3